RxDoctor Payments Data

Christopher Pannucci, MD

Plastic and Reconstructive Surgery · Spokane, WANPI 1083737738

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $9,029 of the $11,397 with a category attached, or 79.2%. Sientra, Inc. accounts for 71.2% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $9,358 and has fallen 90.2% since, to $913 in 2025.

$11,397in general payments, 2019–2025

Across 47 payments — averaging $242.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sientra, Inc.$8K
  • RTI Surgical, Inc$2K
  • AbbVie$927
  • Davol Inc.$234
  • Innovation Technologies Inc$169
  • Revance Therapeutics, Inc.$142
  • plus $306 from 4 others
$43,083in research payments, 2019–2025

Across 6 payments — averaging $7180.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Mentor Worldwide LLC$43K

What the payments were for

  • Consulting fees$9,02979%
  • Food & beverage$2,36821%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,397 in reported general payments places this provider in the 80th percentile of 63 plastic and reconstructive surgery providers in Washington.

See all plastic and reconstructive surgery providers in Washington

Medicare billing

Part B allowed, 2024
$56,474
Medicare patients
26
Services billed
156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ondansetron OdtOndansetron19$185
Oxycodone Hcl18$82

Paid to pharmacies, not to this prescriber.

Other plastic and reconstructive surgery in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →